Journal of Medicinal Chemistry
ARTICLE
3.58 (t, J = 6.24 Hz, 1H), 3.10ꢀ2.87 (m, 4H), 2.39ꢀ2.16 (m, 3H),
2.14ꢀ1.89 (m, 2H), 1.56 (d, J = 7.02 Hz, 3H); 19F NMR (CDCl3)
ꢀ111.60, ꢀ114.06, ꢀ114.62. LCꢀMS method 1, tR = 8.79 min, m/z =
470, purity = 99%. HRMS calcd for C27H26F3NO3 + Na. 492.1762,
found 492.1745.
(13) Walker, B. R.; Andrew, R. Tissue production of cortisol by
11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Ann. N.Y. Acad. Sci. 2006, 1083, 165–184.
(14) Tomlinson, J. W.; Stewart, P. M. Modulation of glucocorticoid
action and the treatment of type-2 diabetes. Best Pract. Res., Clin.
Endocrinol. Metab. 2007, 21, 607–619.
(15) Bertagna, X.; Guignat, L.; Groussin, L.; Bertherat, J. Cushing's
disease. Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 607–623.
(16) Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.;
Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral
obesity and the metabolic syndrome. Science (Washington, DC, U. S.)
2001, 294, 2166–2170.
(17) Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.;
Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G. F.; Fleming,
S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of
glucocorticoid action in adipose tissue causes high blood pressure in
mice. J. Clin. Invest. 2003, 112, 83–90.
(18) Kotelevitsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.;
Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R. W.; Seckl,
J. R.; Mullins, J. J. 11beta-Hydroxysteroid dehydrogenase type 1 knock-
out mice show attenuated glucocorticoid-inducible responses and resist
hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 1997,
94, 14924–14929.
(19) Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes, M. C.;
Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J. R.
Novel adipose tissue-mediated resistance to diet-induced visceral obe-
sity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Diabetes 2004, 53, 931–938.
(20) Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux,
A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile,
hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid
dehydrogenase type 1 null mice. J. Biol. Chem. 2001, 276, 41293–
41300.
(21) Andrews, R. C.; Rooyackers, O.; Walker, B. R. Effects of the
11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on in-
sulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab.
2003, 88, 285–291.
(22) Sandeep, T. C.; Andrew, R.; Homer, N. Z. M.; Andrews, R. C.;
Smith, K.; Walker, B. R. Increased in vivo regeneration of cortisol in
adipose tissue in human obesity and effects of the 11beta-hydroxysteroid
dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005, 54,
872–879.
(23) Barf, T.; Vallgårda, J.; Emond, R.; Haeggstroem, C.; Kurz, G.;
Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.;
Engblom, L.; Edling, N.; Roenquist-Nii, Y.; Oehman, B.; Alberts, P.;
Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential
antidiabetic drugs. Discovery of potent and selective inhibitors of the
11beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45,
3813–3815.
’ ASSOCIATED CONTENT
S
Supporting Information. Synthetic procedures and
b
NMR, MS, and HPLC data on new compounds; assay protocols;
crystallographic data for 25f. This material is available free of
’ AUTHOR INFORMATION
Corresponding Author
*Phone: +1-215-461-2042. Fax: +1-215-461-2006. E-mail: ctice@
vitaerx.com.
’ ABBREVIATIONS USED
HPA, hypothalamicꢀpituitaryꢀadrenal; 11β-HSD1, 11β-hydroxy-
steroid dehydrogenase type 1; 11β-HSD2, 11β-hydroxysteroid
dehydrogenase type 2;DIO, diet-induced obesity; HBA1C, glyco-
sylated hemoglobin
’ REFERENCES
(1) Diabetes Atlas, 4th ed.; IDF: Brussels, Belgium, 2009.
(2) Alberti, K. G. M. M.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.;
Cleeman, J. I.; Donato, K. A.; Fruchart, J.-C.; James, W. P. T.; Loria,
C. M.; Smith, S. C., Jr. Harmonizing the metabolic syndrome: a joint
interim statement of the International Diabetes Federation Task Force
on Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation; Inter-
national Atherosclerosis Society; and International Association for the
Study of Obesity. Circulation 2009, 120, 1640–1645.
(3) Mohler, M. L.; He, Y.; Wu, Z.; Hwang, D. J.; Miller, D. D. Recent
and emerging anti-diabetes targets. Med. Res. Rev. 2009, 29, 125–195.
(4) Tanaka, N.; Nonaka, T.; Nakamura, K. T.; Hara, A. SDR:
structure, mechanism of action, and substrate recognition. Curr. Org.
Chem. 2001, 5, 89–111.
(5) Bray, J. E.; Marsden, B. D.; Oppermann, U. The human short-
chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics
summary. Chem.-Biol. Interact. 2009, 178, 99–109.
(6) Jacobson, L. Hypothalamicꢀpituitaryꢀadrenocortical axis
regulation. Endocrinol. Metab. Clin. North Am. 2005, 34, 271–292.
(7) Harno, E.; White, A. Will treating diabetes with 11beta-HSD1
inhibitors affect the HPA axis? Trends Endocrinol. Metab. 2010, 21,
619–627.
(8) Albiston, A. L.; Obeyesekere, V. R.; Smith, R. E.; Krozowski, Z. S.
Cloning and tissue distribution of the human 11beta-hydroxysteroid
dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 1994, 105,
R11–R17.
(9) Cooper, M. S.; Stewart, P. M. 11beta-Hydroxysteroid dehydro-
genase type 1 and its role in the hypothalamusꢀpituitaryꢀadrenal axis,
metabolic syndrome, and inflammation. J. Clin. Endocrinol. Metab. 2009,
94, 4645–4654.
(10) Wamil, M.; Seckl, J. R. Inhibition of 11beta-hydroxysteroid
dehydrogenase type 1 as a promising therapeutic target. Drug Discovery
Today 2007, 12, 504–520.
(11) Fotsch, C.; Wang, M. Blockade of glucocorticoid excess at the
tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as
a therapy for type 2 diabetes. J. Med. Chem. 2008, 51, 4851–4857.
(12) Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in
metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors.
Curr. Med. Chem. 2008, 15, 642–649.
(24) St. Jean, D. J., Jr.; Wang, M.; Fotsch, C. Inhibitors of 11beta-
HSD1: a potential treatment for the metabolic syndrome. Curr. Top.
Med. Chem. (Sharjah, United Arab Emirates) 2008, 8, 1508–1523.
(25) Boyle, C. D. Recent advances in the discovery of 11beta-HSD1
inhibitors. Curr. Opin. Drug Discovery Dev. 2008, 11, 495–511.
(26) Schnackenberg, C. G. 11beta-Hydroxysteroid dehydrogenase
type 1 inhibitors for metabolic syndrome. Curr. Opin. Invest. Drugs
(Thomson Sci.) 2008, 9, 295–300.
(27) Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen,
H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.;
Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren,
N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack,
A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.;
Thieringer, R. 11beta-HSD1 inhibition ameliorates metabolic syndrome
and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005,
202, 517–527.
(28) Veniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery,
M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.;
Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen,
6061
dx.doi.org/10.1021/jm2005354 |J. Med. Chem. 2011, 54, 6050–6062